tradingkey.logo

Telomir Pharmaceuticals Inc

TELO
View Detailed Chart
1.410USD
+0.040+2.92%
Close 12/19, 16:00ETQuotes delayed by 15 min
47.70MMarket Cap
LossP/E TTM

Telomir Pharmaceuticals Inc

1.410
+0.040+2.92%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.92%

5 Days

-2.76%

1 Month

+1.44%

6 Months

-19.89%

Year to Date

-65.78%

1 Year

-72.78%

View Detailed Chart

Key Insights

Telomir Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 131/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 15.50.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Telomir Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking
131 / 158
Overall Ranking
483 / 4582
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
15.500
Target Price
+999.29%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Telomir Pharmaceuticals Inc Highlights

StrengthsRisks
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -3.85, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.75M shares, decreasing 26.38% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.10M shares of this stock.

Telomir Pharmaceuticals Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Telomir Pharmaceuticals Inc Info

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
Ticker SymbolTELO
CompanyTelomir Pharmaceuticals Inc
CEOAminov (Erez)
Websitehttps://telomirpharma.com/

FAQs

What is the current price of Telomir Pharmaceuticals Inc (TELO)?

The current price of Telomir Pharmaceuticals Inc (TELO) is 1.410.

What is the symbol of Telomir Pharmaceuticals Inc?

The ticker symbol of Telomir Pharmaceuticals Inc is TELO.

What is the 52-week high of Telomir Pharmaceuticals Inc?

The 52-week high of Telomir Pharmaceuticals Inc is 5.400.

What is the 52-week low of Telomir Pharmaceuticals Inc?

The 52-week low of Telomir Pharmaceuticals Inc is 1.120.

What is the market capitalization of Telomir Pharmaceuticals Inc?

The market capitalization of Telomir Pharmaceuticals Inc is 47.70M.

What is the net income of Telomir Pharmaceuticals Inc?

The net income of Telomir Pharmaceuticals Inc is -16.53M.

Is Telomir Pharmaceuticals Inc (TELO) currently rated as Buy, Hold, or Sell?

According to analysts, Telomir Pharmaceuticals Inc (TELO) has an overall rating of --, with a price target of 15.500.

What is the Earnings Per Share (EPS TTM) of Telomir Pharmaceuticals Inc (TELO)?

The Earnings Per Share (EPS TTM) of Telomir Pharmaceuticals Inc (TELO) is -0.367.
KeyAI